Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAUDE study of EO2040 plus nivolumab in ctDNA-defined minimal residual disease colorectal cancer
2022-002679-12Phase 2Completed
- Sponsor
- Enterome
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EO2040 and nivolumab in colorectal cancer (CRC), sponsored by Enterome. Primary endpoint: 6-month ctDNA clearance rate. Started Aug 2022; status: completed.
02
Drugs
EO2040nivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-002679-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002679-12.